SCHEMBL7485486

SCHEMBL7485486

CCOC(=O)c1cn(CC)c2sccc2c1=O

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.57
KDM4E B2RXH2 4/20 0.57
HTT P42858 2/20 0.57
CYP1A2 P05177 1/20 0.57
LMNA P02545 2/20 0.56
TDP1 Q9NUW8 1/20 0.55
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
MAPT P10636 2/20 0.47
THRB P10828 1/20 0.47
POLB P06746 2/20 0.47
HPGD P15428 4/20 0.47
HSD17B10 Q99714 2/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
TSHR P16473 2/20 0.45
MAPK1 P28482 2/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7111537 0.85 BAZ2B (0.47) ALDH1A1KDM4EHTTCYP1A2LMNA
SCHEMBL11557695 0.83 LMNA (0.52) ALDH1A1KDM4EHTTCYP1A2LMNA
SCHEMBL11582138 0.79 ALDH1A1 (0.60) ALDH1A1KDM4EHTTCYP1A2LMNA
SCHEMBL7484080 0.77 LMNA (0.60) ALDH1A1KDM4EHTTCYP1A2LMNA
SCHEMBL10662262 0.76 ALDH1A1 (0.57) ALDH1A1KDM4EHTTCYP1A2LMNA
SCHEMBL7056985 0.76 LMNA (0.69) ALDH1A1KDM4EHTTLMNATDP1
SCHEMBL23937765 0.75 ALDH1A1 (0.40) ALDH1A1KDM4EHTTCYP1A2LMNA
SCHEMBL6284441 0.74 LMNA (0.56) ALDH1A1KDM4EHTTCYP1A2LMNA
SCHEMBL7283936 0.74 TDP1 (0.68) ALDH1A1KDM4EHTTCYP1A2LMNA
SCHEMBL7285360 0.74 LMNA (0.77) ALDH1A1KDM4EHTTCYP1A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6495683-B2 HERPES VIRUS PHARMACIA AND UPJOHN COMPANY 2002-12-17 US disclosed
EP-1159279-B1 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS UPJOHN CO (US) 2002-10-16 EP disclosed
US-20020006937-A1 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-01-17 US disclosed
EP-1159279-A2 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2001-12-05 EP disclosed
US-6239142-B1 HERPES VIRUS INFECTION PHARMACIA & UPJOHN COMPANY 2001-05-29 US disclosed
WO-2000053610-A2 4-OXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2000-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006937-A1 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents IRF3, IL4, ZC3HAV1 ALDH1A1 1869/4885KDM4E 65/4885HTT 4085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.